The CHRYSALIS-2 study, which was reported at ASCO 2023, investigated the effectiveness of amivantamab and lazertinib (3rd generation EGFR TKI) in patients with EGFR-mutated NSCLC who had disease progression on Osimertinib or chemotherapy-naive patients with EGFR exon 19 deletion or L858R mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.